Neuphoria Therapeutics Inc.
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell NEUP and other ETFs, options, and stocks.About NEUP
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.
CEOSpyridon Papapetropoulos
CEOSpyridon Papapetropoulos
Employees8
Employees8
HeadquartersBurlington, Massachusetts
HeadquartersBurlington, Massachusetts
Founded1996
Founded1996
Employees8
Employees8
NEUP Key Statistics
Market cap22.64M
Market cap22.64M
Price-Earnings ratio-0.18
Price-Earnings ratio-0.18
Dividend yield—
Dividend yield—
Average volume72.64K
Average volume72.64K
High today$4.61
High today$4.61
Low today$4.21
Low today$4.21
Open price$4.61
Open price$4.61
Volume109.44K
Volume109.44K
52 Week high$21.40
52 Week high$21.40
52 Week low$2.77
52 Week low$2.77
Stock Snapshot
Neuphoria Therapeutics Inc.(NEUP) stock is priced at $4.21, giving the company a market capitalization of 22.64M. It carries a P/E multiple of -0.18.
During the trading session on 2025-12-11, Neuphoria Therapeutics Inc.(NEUP) shares reached a daily high of $4.61 and a low of $4.21. At a current price of $4.21, the stock is 0.0% higher than the low and still -8.7% under the high.
Trading volume for Neuphoria Therapeutics Inc.(NEUP) stock has reached 109.44K, versus its average volume of 72.64K.
The stock's 52-week range extends from a low of $2.77 to a high of $21.40.
The stock's 52-week range extends from a low of $2.77 to a high of $21.40.
People also own
Based on the portfolios of people who own NEUP. This list is generated using Robinhood data, and it’s not a recommendation.